Claims
- 1. An isolated nucleic acid molecule encoding a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, 7, 11, 13, and 15.
- 2. An isolated nucleic acid molecule encoding a polypeptide selected from the group consisting of:
a) a polypeptide comprising at least 20 contiguous amino acids of SEQ ID NO:2; b) a polypeptide comprising at least 210 contiguous amino acids of SEQ ID NO:7; c) a polypeptide comprising at least 90 contiguous amino acids of SEQ ID NO:11; d) a polypeptide comprising at least 170 contiguous amino acids of SEQ ID NO:13; and e) a polypeptide comprising at least 100 contiguous amino acids of SEQ ID NO:15;
- 3. An isolated nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence selected from the group consisting of:
a) an amino acid sequence that is at least 90% identical to SEQ ID NO:2; b) an amino acid sequence that is at least 90% identical to SEQ ID NO:7; c) an amino acid sequence that is at least 99% identical to SEQ ID NO:11; d) an amino acid sequence that is at least 99.5% identical to SEQ ID NO:13; e) an amino acid sequence that is at least 98% identical to SEQ ID NO:15;
- 4. An isolated nucleic acid molecule comprising nucleotide sequence selected from the group consisting of SEQ ID NO:1, 3, 6, 10, 12, and 14.
- 5. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
a) a nucleotide sequence comprising at least 60 contiguous nucleotides of SEQ ID NO:1 or SEQ ID NO:3; b) a nucleotide sequence comprising at least 630 contiguous nucleotides of SEQ ID NO:6; c) a nucleotide sequence comprising at least 270 contiguous nucleotides of SEQ ID NO:10; d) a nucleotide sequence comprising at least 410 contiguous nucleotides of SEQ ID NO:12; and e) a nucleotide sequence comprising at least 300 contiguous nucleotides of SEQ ID NO:14;
- 6. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
a) a nucleotide sequence comprising at least 25 contiguous nucleotides of SEQ ID NO:1 or SEQ ID NO:3; b) a nucleotide sequence comprising at least 305 contiguous nucleotides of SEQ ID NO:6; c) a nucleotide sequence comprising at least 255 contiguous nucleotides of SEQ ID NO:10; d) a nucleotide sequence comprising at least 310 contiguous nucleotides of SEQ ID NO:12; and e) a nucleotide sequence comprising at least 240 contiguous nucleotides of SEQ ID NO:14;
- 7. An isolated nucleic acid molecule comprising a sequence which is complementary to the sequence of the nucleic acid molecule according to any one of claims 1-5.
- 8. An isolated nucleic acid molecule comprising a sequence which is complementary to the sequence of the nucleic acid molecule according to claim 6.
- 9. An isolated nucleic acid molecule comprising:
a) a nucleotide sequence encoding an extracellular domain of an amino acid sequence selected from the group consisting of SEQ ID NO:2, 7, 11, 13, and 15; and b) a nucleotide sequence encoding an Fc domain of immunoglobulin G.
- 10. A vector comprising the nucleic acid molecule according to any one of claims 1-6.
- 11. A vector comprising the nucleic acid molecule according to any one of claims 7-8.
- 12. A vector comprising the nucleic acid molecule according to claim 9.
- 13. A host cell comprising the vector according to claim 10, wherein the host cell is selected from the group consisting of bacterial, yeast, insect, mammalian, and plant cells.
- 14. A host cell comprising the vector according to claim 11, wherein the host cell is selected from the group consisting of bacterial, yeast, insect, mammalian, and plant cells.
- 15. A host cell comprising the vector according to claim 12, wherein the host cell is selected from the group consisting of bacterial, yeast, insect, mammalian, and plant cells.
- 16. An isolated polypeptide encoded by the nucleic acid molecule according to any one of claims 1-5.
- 17. An isolated polypeptide encoded by the nucleic acid molecule according to claim 9.
- 18. An isolated antibody that binds to the polypeptide according to claim 16.
- 19. The antibody according to claim 18 which is monoclonal.
- 20. A hybridoma cell which produces the antibody according to claim 19.
- 21. A pharmaceutical composition comprising the nucleic acid molecule according to claim 8, and a physiologically acceptable carrier, excipient, or diluent.
- 22. A pharmaceutical composition comprising the host cell according to claim 13, and a physiologically acceptable carrier, excipient, or diluent.
- 23. A pharmaceutical composition comprising the polypeptide according to claim 15, and a physiologically acceptable carrier, excipient, or diluent.
- 24. A pharmaceutical composition comprising the polypeptide according to claim 16, and a physiologically acceptable carrier, excipient, or diluent.
- 25. A pharmaceutical composition comprising the antibody according to claim 19, and a physiologically acceptable carrier, excipient, or diluent.
- 26. A method of identifying a ligand which binds to a B7-related polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, 7, 11, 13, and 15, comprising:
a) providing a solid support having attached thereto the B7-related polypeptide; b) contacting the support with polypeptides obtained from a biological sample, and incubating the support under conditions to allow one or more sample polypeptides to associate with the B7-related polypeptide; and c) determining whether B7-related polypeptide associates with one or more sample polypeptides, thereby identifying a ligand that binds to the B7-related polypeptide.
- 27. A method of identifying a test agent which binds to a B7-related polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, 7, 11, 13, and 15, comprising:
a) providing a solid support having attached thereto the B7-related polypeptide; b) contacting the support with test agents, and incubating the support under conditions to allow one or more test agents to associate with the B7-related polypeptide; and c) determining whether B7-related polypeptide associates with one or more test agents, thereby identifying a test agent that binds to the B7-related polypeptide.
- 28. A method of increasing or decreasing T-cell activity in a subject comprising: administering to the subject the pharmaceutical composition according to any one of claims 21-25 in an amount effective to increase or decrease immune cell activity.
- 29. The method according to claim 28, wherein the subject is diagnosed with a viral infection.
- 30. The method according to claim 29, wherein the viral infection is selected from the group consisting of human immunodeficiency virus, human papilloma virus, herpes simplex virus, human encephalitis virus, human rhinovirus, and human influenza virus infections.
- 31. The method according to claim 28, wherein the subject is diagnosed with cancer.
- 32. The method according to claim 28, wherein the subject is diagnosed with a condition selected from the group consisting of tissue rejection, bone marrow rejection, organ transplant rejection, and graft versus host disease.
- 33. The method according to claim 28, wherein the subject is diagnosed with condition associated with inflammation.
- 34. The method according to claim 33, wherein the condition is selected from the group consisting of psoriasis, chronic obstructive pulmonary disease, asthma, and atherosclerosis.
- 35. The method according to claim 28, wherein the subject is diagnosed with an autoimmune disease.
- 36. The method according to claim 35, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, Lupus erythematosus, Hashimoto's thyroiditis, primary mixedema, Graves' disease, pernicious anemia, autoimmune atrophic gastritis, insulin dependent diabetes mellitus, good pasture's syndrome, myasthenia gravis, pemphigus, Crohn's disease, sympathetic opthalmia, autoimmune uveitis, autoimmune hemolytic anemis, idiopathic thrombocytopenia, primary biliary cirrhosis, ulcerative colitis, Sjogren's syndrome, polymyositis, and mixed connective tissue disease.
- 37. A method of diagnosing a condition which is associated with increased immune cell activity, comprising:
a) contacting the isolated nucleic acid of any one of claims 6 and 8 with a biological sample under high stringency conditions that allow the nucleic acid to hybridize to a nucleic acid in the sample, and thereby form a complex; b) measuring the hybridization complex of (a); and c) comparing the amount of hybridization complex of (a) to an amount of hybridization complex in a standard biological sample, wherein an increase from the standard amount indicates diagnosis of the condition.
- 38. The method according to claim 37, wherein the condition is selected from the group consisting of tissue rejection, bone marrow rejection, organ transplant rejection, and graft versus host disease.
- 39. The method according to claim 37, wherein the condition is associated with inflammation.
- 40. The method according to claim 37, wherein the condition is selected from the group consisting of psoriasis, chronic obstructive pulmonary disease, asthma, and atherosclerosis.
- 41. The method according to claim 37, wherein the condition is an autoimmune disease.
- 42. The method of claim 41, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, Lupus erythematosus, Hashimoto's thyroiditis, primary mixedema, Graves' disease, pernicious anemia, autoimmune atrophic gastritis, insulin dependent diabetes mellitus, good pasture's syndrome, myasthenia gravis, pemphigus, Crohn's disease, sympathetic opthalmia, autoimmune uveitis, autoimmune hemolytic anemis, idiopathic thrombocytopenia, primary biliary cirrhosis, ulcerative colitis, Sjogren's syndrome, polymyositis, and mixed connective tissue disease.
- 43. A method of diagnosing a condition which is associated with increased immune cell activity, comprising:
a) contacting the isolated antibody of claim 19 with a biological sample under conditions that allow the antibody to bind to an amino acid sequence in the sample, and thereby form a complex; b) detecting the complex of (a); and c) comparing the amount of complex of (a) to an amount of complex in a standard biological sample, wherein an increase from the standard amount indicates diagnosis of the condition.
- 44. The method according to claim 43, wherein the condition is selected from the group consisting of tissue rejection, bone marrow rejection, organ transplant rejection, and graft versus host disease.
- 45. The method according to claim 43, wherein the condition is associated with inflammation.
- 46. The method according to claim 45, wherein the condition is selected from the group consisting of psoriasis, chronic obstructive pulmonary disease, asthma, and atherosclerosis.
- 47. The method according to claim 43, wherein the condition is an autoimmune disease.
- 48. The method of claim 47, wherein the disorder is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, Lupus erythematosus, Hashimoto's thyroiditis, primary mixedema, Graves' disease, pernicious anemia, autoimmune atrophic gastritis, insulin dependent diabetes mellitus, good pasture's syndrome, myasthenia gravis, pemphigus, Crohn's disease, sympathetic opthalmia, autoimmune uveitis, autoimmune hemolytic anemis, idiopathic thrombocytopenia, primary biliary cirrhosis, ulcerative colitis, Sjogren's syndrome, polymyositis, and mixed connective tissue disease.
- 49. A kit for detecting a B7-related nucleic acid molecule comprising:
a) the isolated nucleic acid molecule according to any one of claims 6 or 8; and b) at least one component to detect binding of the isolated nucleic acid molecule to a B7-related nucleic acid molecule.
- 50. A kit for detecting a B7-related polypeptide comprising:
a) the isolated antibody of claim 19; and b) at least one component to detect binding of the isolated antibody to a B7-related polypeptide sequence.
- 51. A transgenic mouse comprising the nucleic acid molecule according to any one of claims 1-6.
- 52. A cell line comprising the nucleic acid molecule according to any one of claims 1-6.
RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. Application Ser. No. 60/209,811, filed Jun. 6, 2000, and U.S. Application Ser. No. 60/272,107, filed Feb. 28, 2001, which are incorporated by reference in their entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60209811 |
Jun 2000 |
US |
|
60272107 |
Feb 2001 |
US |